Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Cited by (1,000)

Items 401–500 of 1,000

1. Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants
   Lucia Saldaña-Rivera, Martiniano Bello, David Méndez-Luna · 2018 · Journal of Biomolecular Structure and Dynamics
2. EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
   Daniel Sentana‐Lledo, Emmeline C. Academia, Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, Paul A. VanderLaan, Daniel Botelho Costa · 2023 · Translational Lung Cancer Research
3. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma
   Jie Xu, Li‐Fan Zeng, Weihua Shen, John J. Turchi, Zhong‐Yin Zhang · 2013 · Biochemical and Biophysical Research Communications
4. Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia
   Weiyan Cheng, Shijun Zhu, Xiaodong Ma, Ni Qiu, Peng Peng, Rong Sheng, Yongzhou Hu · 2014 · European Journal of Medicinal Chemistry
5. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer
   Ranee Mehra, Ilya G. Serebriiskii, Roland L. Dunbrack, Matthew K. Robinson, Barbara Ann Burtness, Erica A. Golemis · 2011 · Drug Resistance Updates
6. Synthesis, in vitro antitumor activity and molecular modeling studies of a new series of benzothiazole Schiff bases
   Moustafa Tarek Gabr, Nadia S. El‐Gohary, Eman R. El‐Bendary, Mohamed M. El‐Kerdawy, Nanting Ni · 2016 · Chinese Chemical Letters
7. StructMAn: annotation of single-nucleotide polymorphisms in the structural context
   Alexander Greß, Vasily E. Ramensky, Joachim Büch, Andreas Keller, Olga V. Kalinina · 2016 · Nucleic Acids Research
8. Structure–Activity Relationships of Hexahydrocyclopenta[c]quinoline Derivatives as Allosteric Inhibitors of CDK2 and EGFR
   Luca Carlino, Michael S. Christodoulou, Valentina Restelli, Fabiana Caporuscio, Francesca Foschi, Marta Stefania Semrau, Elisa Costanzi, Annachiara Tinivella, Luca Pinzi, Leonardo Lo Presti et al. · 2018 · ChemMedChem
9. The structure-function relationship of oncogenic LMTK3
   Angeliki Ditsiou, Chiara Cilibrasi, Nikiana Simigdala, Athanasios Papakyriakou, Leanne Milton‐Harris, Viviana Vella, Joanne E. Nettleship, Jae Ho Lo, Shivani Soni, Goar Smbatyan et al. · 2020 · Science Advances
10. Prediction of kinase inhibitors binding modes with machine learning and reduced descriptor sets
    Ibrahim Abdelbaky, Hilal Tayara, Kil To Chong · 2021 · Scientific Reports
11. Molecular dynamics simulation reveals structural and thermodynamic features of kinase activation by cancer mutations within the epidermal growth factor receptor
    Shunzhou Wan, Peter V. Coveney · 2011 · Journal of Computational Chemistry
12. A Network of Hydrophobic Residues Impeding Helix αC Rotation Maintains Latency of Kinase Gcn2, Which Phosphorylates the α Subunit of Translation Initiation Factor 2
    Andrés Gárriz, Hongfang Qiu, Madhusudan Dey, Eun-Joo Seo, Thomas E. Dever, Alan G. Hinnebusch · 2008 · Molecular and Cellular Biology
13. Flavonoids as a scaffold for development of novel anti-angiogenic agents: An experimental and computational enquiry
    Rajesh Nivarti Gacche, Rohan J. Meshram, Harshala D. Shegokar, Dhananjay S. Gond, Sonali Shankar Kamble, Vivek N. Dhabadge, Bhimashankar Gurushidhappa Utage, Kapil K. Patil, Rahul Ashokrao More · 2015 · Archives of Biochemistry and Biophysics
14. Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome
    Gerald S. M. A. Kerner, Ed M. D. Schuuring, Johanna Sietsma, T. Jeroen N. Hiltermann, Remge M. Pieterman, Gerard P. J. de Leede, John W.G. van Putten, Jeroen J.W. Liesker, Tineke E. J. Renkema, Peter van Hengel et al. · 2013 · PLoS ONE
15. Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere
    Rainer Wilcken, Markus O. Zimmermann, Matthias R. Bauer, Trevor J. Rutherford, Alan Roy Fersht, Andreas C. Joerger, Frank M. Boeckler · 2015 · ACS Chemical Biology
16. Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties
    Shilin Xu, Tianfeng Xu, Lianwen Zhang, Zhang Zhang, Jinfeng Luo, Yingxue Liu, Xiaoyun Lu, Zhengchao Tu, Xiaomei Ren, Ke Ding · 2013 · Journal of Medicinal Chemistry
17. Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
    Filippo Papini, Janani Sundaresan, Alessandro Leonetti, Marcello Tiseo, Christian Diego Rolfo, Godefridus J. Peters, Elisa Giovannetti · 2021 · Critical Reviews in Oncology/Hematology
18. Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer
    P. Anoosha, Liang‐Tsung Huang, Ramasamy Sakthivel, Devarajan Karunagaran, M. Michael Gromiha · 2015 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
19. Anticancer drug response prediction integrating multi-omics pathway-based difference features and multiple deep learning techniques
    Yang‐Chang Wu, Ming Chen, Yufang Qin · 2025 · PLoS Computational Biology
20. Assessing the Accuracy of Two Enhanced Sampling Methods Using EGFR Kinase Transition Pathways: The Influence of Collective Variable Choice
    Albert C. Pan, Thomas M. Weinreich, Yibing Shan, Daniele Paolo Scarpazza, David Elliot Shaw · 2014 · Journal of Chemical Theory and Computation
21. Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
    F. Concha-Benavente, R. Ferris · 2017 · Frontiers in Pharmacology
22. Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities
    Amna Ghith, Nasser S. M. Ismail, Khairia M. Youssef, Khaled A. M. Abouzid · 2017 · Archiv der Pharmazie
23. Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer
    Jianhua Mao, Lie Ma, Yan Shen, Kongkai Zhu, Ru Zhang, Wenda Xi, Zheng Ruan, Cheng Yu Luo, Zhu Chen, Xiaodong Xi et al. · 2018 · Cell Death and Disease
24. Investigating the Impact of Different Acrylamide (Electrophilic Warhead) on Osimertinib’s Pharmacological Spectrum by Molecular Mechanic and Quantum Mechanic Approach
    Harun Patel, Iqrar Ahmad, Harsha Jadhav, Rahul H. Pawara, Deepak K. Lokwani, Sanjay Javerilal Surana · 2020 · Combinatorial Chemistry & High Throughput Screening
25. Targeting RAS oncogenesis with SOS1 inhibitors
    Roman Christian Hillig, Benjamin Bader · 2022 · Advances in cancer research
26. Synthesis and biological assessment of indole derivatives containing penta-heterocycles scaffold as novel anticancer agents towards A549 and K562 cells
    Guanglong Zhang, Zhenhua Tang, Sili Fan, Cheng‐Peng Li, Yan Li, Weiqin Liu, Xuesha Long, Wenjing Zhang, Yi Zhang, Zhurui Li et al. · 2023 · Journal of Enzyme Inhibition and Medicinal Chemistry
27. Transcriptional Profiling of Non-Small Cell Lung Cancer Cells with Activating EGFR Somatic Mutations
    Kuicheon C. Choi, Chad J. Creighton, David N. Stivers, Nobukazu Fujimoto, Jonathan M. Kurie · 2007 · PLoS ONE
28. A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
    Nadine Demierre, Vincent Zoete, Olivier Alain Michielin, Edouard Stauffer, Dieter R. Zimmermann, Daniel C. Betticher, Solange Peters · 2013 · Lung Cancer
29. Design, synthesis of benzimidazole tethered 3,4-dihydro-2H-benzo[e] [1, 3] oxazines as anticancer agents
    Srinivas Gali, D. Raghu, Veerabhadraiah Mallikanti, Vishnu Thumma, Namratha Vaddiraju · 2023 · Molecular Diversity
30. Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC
    Emiliano Laudadio, Luca Mangano, Cristina Minnelli · 2024 · ACS Chemical Biology
31. Discovery of novel selective inhibitors for EGFR-T790M/L858R
    Fang Bai, Hongyan Liu, Linjiang Tong, Wei Zhou, Li Liu, Zhenjiang Zhao, Xiaofeng Liu, Hualiang Jiang, Xicheng Wang, Hua Xie et al. · 2011 · Bioorganic & Medicinal Chemistry Letters
32. Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity
    Svein Jacob Kaspersen, Jin Han, Kristin G. Nørsett, Line Rydså, Eli Kjøbli, Steffen Bugge, Geir Bjørkøy, Eirik Sundby, Bård Helge Hoff · 2014 · European Journal of Pharmaceutical Sciences
33. Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation
    Athanasios Papakyriakou, Dionisios Vourloumis, Fotini F Tzortzatou-Stathopoulou, Michael Karpusas · 2008 · Proteins Structure Function and Bioinformatics
34. Inhibition of epidermal growth factor receptor by ferulic acid and 4-vinylguaiacol in human breast cancer cells
    Sudhagar Selvaraju, Shanmugaraj Sathya, R. Anuradha, G. Gokulapriya, Y. Geetharani, Baddireddi Subhadra Lakshmi · 2017 · Biotechnology Letters
35. Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor
    Jaebong Jang, Jieun Son, Eunyoung Park, Takayuki Kosaka, Jamie A. Saxon, Dries J.H. De Clercq, Hwan Geun Choi, Junko Tanizaki, Michael J. Eck, Pasi Antero Janne et al. · 2018 · Angewandte Chemie International Edition
36. Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
    Juliana F. Vilachã, Sarah C. Mitchel, Muluembet Z. Akele, Stephen Evans, Matthew R. Groves · 2020 · Crystals
37. Targeting EGFR degradation by autophagosome degraders
    ZhongFeng Zhu, Jiaying Li, Shujun Shen, Hawaa Al-furas, Shengrong Li, Yichen Tong, Yi Li, Yucheng Zeng, Qianyi Feng, Kaiyue Chen et al. · 2024 · European Journal of Medicinal Chemistry
38. Design, microwave-mediated synthesis and biological evaluation of novel 4-aryl(alkyl)amino-3-nitroquinoline and 2,4-diaryl(dialkyl)amino-3-nitroquinolines as anticancer agents
    Monika Chauhan, Anil Rana, Jimi Marin Alex, Arvind Negi, Sandeep Singh, Raj Kumar · 2014 · Bioorganic Chemistry
39. A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping
    Angela Zupa, Giuseppina Improta, Alessandra Silvestri, Elisa Pin, Jianghong Deng, Michele Aieta, Pellegrino Musto, Donato Nitti, Enzo Mammano, Lance A. Liotta et al. · 2012 · Journal of Thoracic Oncology
40. MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
    Elena Ortiz Zapater, Richard W. Lee, William Jason Owen, Gregory E. Weitsman, Gilbert O. Fruhwirth, Robert G Dunn, Michael J. Neat, Frank M. McCaughan, Peter J. Parker, Tony Ng et al. · 2017 · PLoS ONE
41. EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise the effectiveness in lung cancer
    Lixian Yang, Shilong Ying, Shiman Hu, Xiangtong Zhao, Muchun Li, Miaoqin Chen, Yiran Zhu, Ping Song, Liyuan Zhu, Tingting Jiang et al. · 2019 · Signal Transduction and Targeted Therapy
42. Synthesis, anti-cancer activity, gene expression and docking stimulation of 2-thioxoimidazolidin-4-one derivatives
    Ghada H. Elsayed, Asmaa Mahmoud Fahim, Ahmed I. A. Khodair · 2022 · Journal of Molecular Structure
43. Pharmacological characterization of MP‐412 (AV‐412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor
    Tsuyoshi Suzuki, Akihiro Fujii, Junichi Ohya, Yusaku Amano, Yasunori Kitano, Daisuke Abe, Hideo Nakamura · 2007 · Cancer Science
44. Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients
    Marzena Anna Lewandowska, Wojciech Jóźwicki, Cezary Jochymski, Janusz Kowalewski · 2013 · Oncology Reports
45. Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors
    Feng Zhao, Zhaohu Lin, Feng Yun Wang, Weili Zhao, Xiaochun Dong · 2013 · Bioorganic & Medicinal Chemistry Letters
46. Evaluating the utility of the HTRF® Transcreener™ ADP assay technology: A comparison with the standard HTRF assay technology
    Lin Hong, Christopher M. Quinn, Yong Jia · 2009 · Analytical Biochemistry
47. Setting the Benchmark For Tailoring Treatment With Egfr Tyrosine Kinase Inhibitors
    Rafael Rosell, Miquel Tarón, José Javier Sánchez, Luis G Paz-Ares · 2007 · Future Oncology
48. Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors
    Jennifer L. Macdonald-Obermann, LINDA JOY PIKE · 2018 · Journal of Biological Chemistry
49. Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib
    Ha‐Na Oh, Mee‐Hyun Lee, Eunae Kim, Ah‐Won Kwak, Ji‐Hye Seo, Goo Yoon, Seung‐Sik Cho, Joon‐Seok Choi, Sang‐Myeong Lee, K. S. Seo et al. · 2019 · Phytotherapy Research
50. Synthesis, antimicrobial, antitumor activity, docking simulation, theoretical studies, and electrochemical analysis of novel Cd(II), Co(II), Cu(II), and Fe(III) complexes containing barbituric moiety
    Asmaa Mahmoud Fahim, Hend Samy Magar, Nelly H. Mahmoud · 2023 · Applied Organometallic Chemistry
51. Design and synthesis of Meldrum's acid based 7-azaindole anchored 1,2,3-triazole hybrids as anticancer agents
    Murali Krishna Vanga, Rambabu Bhukya, Vishnu Thumma, S. S. S. S. Sudha Ambadipudi, V. Lakshma Nayak, Sai Balaji Andugulapati, Vijjulatha Manga · 2024 · RSC Medicinal Chemistry
52. Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP‐C promoter
    Kadoaki Ohashi, Kammei Rai, Yoshiro Fujiwara, Masahiro Osawa, Seiki Hirano, Katsuyoshi Takata, Eisei Kondo, Tadashi Yoshino, Minoru Takata, Mitsune Tanimoto et al. · 2008 · Cancer Science
53. Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents
    Giang Le-Nhat-Thuy, Thuy Van Dinh, Hai Pham‐The, Hung Nguyen Quang, Nga Nguyễn Thị, Tuyet Anh Dang Thi, Phượng Hoàng Thị, Tu Anh Le Thi, Ha Thanh Nguyen, Phuong Nguyen Thanh et al. · 2018 · Bioorganic & Medicinal Chemistry Letters
54. Arylidenes of Quinolin-2-one scaffold as Erlotinib analogues with activities against leukemia through inhibition of EGFR TK/ STAT-3 pathways
    Mohammed A. I. Elbastawesy, Mohamed A. Ramadan, Yaseen A. M. M. Elshaier, Ashraf A. Aly, Gamal El‐Din A. Abuo‐Rahma · 2020 · Bioorganic Chemistry
55. Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization
    Barney Yoo, Kai Ma, Li Zhang, Andrew Burns, Sonia M. Sequeira, Ingo K. Mellinghoff, Cameron Walter Brennan, Ulrich B. Wiesner, Michelle S. Bradbury · 2015 · Bioorganic & Medicinal Chemistry
56. Conformational Transition Pathways of Epidermal Growth Factor Receptor Kinase Domain from Multiple Molecular Dynamics Simulations and Bayesian Clustering
    Yan Li, Xiang Li, Weiya Ma, Zigang Dong · 2014 · Journal of Chemical Theory and Computation
57. A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations
    Gregory Ryslik, Yu‐Wei Cheng, Kei-Hoi Cheung, Yorgo Modis, Hongyu Zhao · 2014 · BMC Bioinformatics
58. ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
    Sunil Kumar Joshi, Jamie M. Keck, Christopher A. Eide, Daniel Bottomly, Elie A. Traer, Jeffrey W Tyner, Shannon K. McWeeney, Cristina E. Tognon, Brian J. Druker · 2020 · Leukemia
59. A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations
    L. Villaruz, X. Wang, Erin Marie Bertino, Linping Gu, Scott Joseph Antonia, Timothy Francis Burns, Jeffrey Melson Clarke, Jeffrey Crawford, Terry L. Evans, David Friedland et al. · 2023 · ESMO Open
60. Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor
    Debanjan Bhattacharjee, Jaweria Bakar, Surbhi P. Chitnis, Erin L. Sausville, Kumar Dilip Ashtekar, Brianna E. Mendelson, Kaitlin Long, Joan C. Smith, David E. Heppner, Jason M. Sheltzer · 2023 · Cell chemical biology
61. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Kenzo Soejima, Hiroyuki Yasuda, Toshiyuki Hirano · 2016 · Expert Review of Clinical Pharmacology
62. Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines
    Lu Zhang, Jun Li, Jing Rong Hu, Dandan Li, Xiaohui Wang, Rui Zhang, Hui Zhang, Meng Qiong Shi, Hong Chen · 2017 · Lung Cancer
63. Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations
    Napat Songtawee, M. Paul Gleeson, Kiattawee Choowongkomon · 2012 · Journal of Molecular Modeling
64. Design, Synthesis and Mechanistic Studies of Novel Imidazo[1,2-A]Pyridines as Anticancer Agents
    Ahmed S. Ismael, Noha H. Amin, Mohammed T. El‐Saadi, Hamdy Mohamed Abdel-Rahman · 2022 · SSRN Electronic Journal
65. A Brief Perspective of Drug Resistance Toward Egfr Inhibitors: The Crystal Structures of Egfrs and Their Variants
    Haixing Guan, Yongli Du, Ning Yang, Xin Cao · 2017 · Future Medicinal Chemistry
66. Molecular structure, spectroscopic (FT-IR, FT-Raman) studies, Homo–Lumo and Fukui function calculations of 2-Acetyl amino-5-bromo- 4 methyl pyridine by density functional theory
    K.R. Santhy, M. Daniel Sweetlin, S. Muthu, Christina Susan Abraham, M. Raja · 2019 · Chemical Data Collections
67. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
    Byoungsan Choi, Minkwon Cha, Gee Sung Eun, Dae Hee Lee, Seul Lee, Muhammad Ehsan, Pil Seok Chae, Won Do Heo, YongKeun Park, Tae‐Young Yoon · 2020 · eLife
68. Introducing a pyrazolopyrimidine as a multi-tyrosine kinase inhibitor, using multi-QSAR and docking methods
    Asrin Bahmani, Hamid Tanzadehpanah, Neda Hosseinpour Moghadam, Massoud Saidijam · 2020 · Molecular Diversity
69. A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients
    Jiachen Xu, Wei Wu, Chunyan Wu, Yong Mao, Xiaowei Qi, Lin Guo, Renquan Lu, Shuhong Xie, Jiatao Lou, Yu Zhang et al. · 2021 · Translational Lung Cancer Research
70. Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase
    Christopher Swale, Valéria Bellini, Matthew W. Bowler, Flore Nardella, Marie‐Pierre Brenier‐Pinchart, Dominique Cannella, Lucid Belmudes, Caroline Mas, Yohann Couté, Fabrice Laurent et al. · 2022 · Science Translational Medicine
71. Nitrobenzamido substitution on thiophene-3-carboxylate: Electrochemical investigation, antioxidant activity, molecular docking, DFT calculations
    Goncagül Serdaroğlu, Nesimi Uludağ, Naki Çolak, P. Richard Rajkumar · 2022 · Journal of Molecular Structure
72. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy
    Jeroen Claus, Gargi Surendra Patel, Tony Ng, Peter J. Parker · 2014 · Biochemical Society Transactions
73. Structural and Energetic Analyses of SNPs in Drug Targets and Implications for Drug Therapy
    Huiyong Sun, Feng‐Qin Ji, Liang-Yu Fu, Zhongyi Wang, Hongyu Zhang · 2013 · Journal of Chemical Information and Modeling
74. Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases
    Kosuke Hashimoto, Igor B. Rogozin, Anna R. Panchenko · 2012 · Human Mutation
75. Novel quinazolin-4-one based derivatives bearing 1,2,3-triazole and glycoside moieties as potential cytotoxic agents through dual EGFR and VEGFR-2 inhibitory activity
    Adel A.‐H. Abdel‐Rahman, Mohamed N. El‐Bayaa, Asmaa Sobhy, Eman M. El-Ganzoury, Eman Samir Nossier, Hanem Mohamed Awad, Wael A. El‐Sayed · 2024 · Scientific Reports
76. Saturation profiling of drug-resistant genetic variants using prime editing
    Younggwang Kim, Hyeong-Cheol Oh, Seung‐Ho Lee, Seokjoong Kim · 2024 · Nature Biotechnology
77. Annual review of EGFR inhibitors in 2024
    Chao Gao, Wanning Wang, Tong Liu, Xingyu Li, Yongbo Yu, Jianhui Wu · 2025 · European Journal of Medicinal Chemistry
78. Leak Proof PDBBind: A Reorganized Data Set of Protein–Ligand Complexes for More Generalizable Binding Affinity Prediction
    Jie Li, Xingyi Guan, Oufan Zhang, Kunyang Sun, Yingze Wang, Dorian Bagni, Teresa L. Head-Gordon · 2026 · The Journal of Physical Chemistry B
79. Capillary Isoelectric-Focusing Immunoassays to Study Dynamic Oncoprotein Phosphorylation and Drug Response to Targeted Therapies in Non–Small Cell Lung Cancer
    Jin‐Qiu Chen, Jih‐Hsiang Lee, Michelle A. Herrmann, Kang‐Seo Park, Madeleine R. Heldman, Paul K. Goldsmith, Yisong Wang, Giuseppe Giaccone · 2013 · Molecular Cancer Therapeutics
80. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells
    Jonatan Darr, Agnes Klochendler, Sara Isaac, Tamar Geiger, Amir Eden · 2015 · Molecular Cancer
81. Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases
    Janina Niggenaber, Julia Hardick, Jonas Lategahn, Daniel Rauh · 2019 · Journal of Medicinal Chemistry
82. A Novel Rhynchophylline Analog, Y396, Inhibits Endothelial Dysfunction Induced by Oxidative Stress in Diabetes Through Epidermal Growth Factor Receptor
    Zhijun Wang, Ling-Ling Chang, Jian Wu, Hongming Pan, Qiu-Yan Zhang, Minjun Wang, Xiaoming Xin, Shanshan Luo, Jian Chen, Xianfeng Gu et al. · 2019 · Antioxidants and Redox Signaling
83. Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
    Abdulaziz B. Hamid, Ruben C. Petreaca · 2020 · Cancers
84. Landscape of drug-resistance mutations in kinase regulatory hotspots
    Pora Kim, Hanyang Li, Junmei Wang, Zhongming Zhao · 2020 · Briefings in Bioinformatics
85. Therapeutic implications of immune‐profiling and EGFR expression in salivary gland carcinoma
    Emily Guazzo, Caroline Louise Cooper, Lisa Wilkinson, Sophie Feng, Brigid King, Fiona Simpson, Sandro Virgilio Porceddu, Benedict James Panizza, Jermaine Ian George Coward · 2020 · Head & Neck
86. Development of new bioactive molecules to treat breast and lung cancer with natural myricetin and its derivatives: A computational and SAR approach
    Shopnil Akash, Ajoy Kumer, Md. Mominur Rahman, Talha Bin Emran, Rohit Sharma, Rajeev Kumar Singla, Fahad Abdulrahman Alhumaydhi, Mayeen Uddin Khandaker, Moon Nyeo Park, Abubakr Mustafa Idris et al. · 2022 · Frontiers in Cellular and Infection Microbiology
87. Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations
    Tadaaki Yamada, Shinji Takeuchi, Naoya Fujita, Akito Nakamura, Wei Wang, Q Li, M. Oda, Tetsuya Mitsudomi, Yasushi Yatabe, Yoshitaka Sekido et al. · 2012 · Oncogene
88. Intracellular pH dynamics and charge-changing somatic mutations in cancer
    Katharine A. White, Kyle P. Kisor, Diane L. Barber · 2019 · Cancer and Metastasis Reviews
89. Synthesis and evaluation of anticancer activity of novel andrographolide derivatives
    Ponnam Devendar, Vadithe Lakshma Nayak, Dharmendra Kumar Yadav, Niranjan Kumar Arigari, Jonnala Kotesh Kumar, KVN Satya Srinivas, Balasubramanian Sridhar, Feroz Khan, Pandu Sastry Kakaraparthi, Ramakrishna Sistla · 2015 · MedChemComm
90. Lazertinib: breaking the mold of third-generation EGFR inhibitors
    Kishan B. Patel, David E. Heppner · 2025 · RSC Medicinal Chemistry
91. Current progress of 1,2,3-triazole hybrids as EGFR inhibitors for cancer therapy – a literature review
    Hussam Elddin Nabieh Khasawneh, Hesham M. Hassan, Amal Ali Alharbi, Wesam Taher Almagharbeh, Raed Fanoukh Aboqader Al-Aouadi, Kirandeep Kaur, Ramya Maranan, Hadeer M. Farhan, Hamada Hashem, Mariam M. Hassan et al. · 2025 · RSC Advances
92. Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants
    Byung Min Chung · 2014 · World Journal of Clinical Oncology
93. Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer
    Teresa Kaserer, Julian Blagg · 2018 · Cell chemical biology
94. Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer
    Tara Spence, Sheron Perera, Jessica Weiss, Sylvie Grenier, Laura Ranich, Frances A. Shepherd, Tracy L. Stockley · 2020 · Journal of Clinical Pathology
95. Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
    Mahlet Z. Tamirat, Kari J. Kurppa, Klaus Elenius, Mark S. Johnson · 2021 · Cancers
96. Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain
    Matheus M de Gunst, Mariëlle I. Gallegos-Ruiz, Giuseppe Giaccone, José Antonio Rodríguez · 2007 · Molecular Cancer
97. Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review
    Xiaoli Zhu, Qianming Bai, Yongming Lu, Peng Qi, Jianhui Ding, Jialei Wang, Xiaoyan Zhou · 2016 · Targeted Oncology
98. Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
    Chen Hu, Aoli Wang, Hong Wu, Ziping Qi, Xixiang Li, Xiao-E Yan, Chen Cheng, Kailin Yu, Fengming Zou, Wenchao Wang et al. · 2017 · Oncotarget
99. Screening of epidermal growth factor receptor inhibitors in natural products by capillary electrophoresis combined with high performance liquid chromatography–tandem mass spectrometry
    Feng Li, Yanmei Zhang, Danye Qiu, Jingwu Kang · 2015 · Journal of Chromatography A
100. Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice
     Kadoaki Ohashi, Nagio Takigawa, Masahiro Osawa, Eiki Ichihara, Hiromasa Takeda, Toshio Kubo, Seiki Hirano, Tadashi Yoshino, Minoru Takata, Mitsune Tanimoto et al. · 2009 · Cancer Research